Drug news
IMPACT study for Provenge (Dendreon) effect in Prostate Cancer questioned
Marie Huber in a paper in the Journal of the National Cancer Institute argues that Provenge (sipuleucel-T)from Dendreon extended survival because older men in the IMPACT study who did not receive Provenge died months sooner than similar patients in other studies possibly due to leukapheresis. She argues that the placebo they received was actually harmful making the Provenge effect appear more positive. The data in IMPACT showed Provenge did not shrink tumours but extended overall survival but there was no efficacy in young men.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins